SOURCE: Delcath Systems, Inc.

October 21, 2008 08:49 ET

Delcath Systems' President and CEO Richard Taney to Present at Two Medical Technology Conferences

NEW YORK, NY--(Marketwire - October 21, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) a leading developer of regional therapy for liver cancer announced today that President and CEO Richard Taney will participate in a Panel Discussion on "Combination Products: A Convergence of Technologies and Market Opportunities" at the Medical Device & Manufacturing Conference, Oct 22, 2008, 12:30pm-1:15pm at the Minneapolis Convention Center. Mr. Taney will also be making a presentation on the Delcath PHP technology at the Investment in Innovation (In3) East Conference to be held on October 23rd, 9:30am-10:00am at the Westin Copley Place in Boston.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Contact Information

  • Company Contact:
    Delcath Systems, Inc.
    Richard Taney
    (212) 489-2100
    Email Contact

    Investor Relations Contact:
    Strategic Growth International, Inc.
    Richard E. Cooper
    (212) 838-1444
    Email Contact

    Public Relations Contact:
    Rubenstein Associates, Inc.
    Robin Wagge
    (212) 843-8006
    Email Contact